|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 美国临床肿瘤学会IV期非小细胞肺癌化疗的临床实践指南更新显示文摘本文旨在为IV期非小细胞肺癌患者的治疗提供更新版推荐。本文资料检索源自2002年以来公布的相关随机试验文献。此指南范围限于化疗与生物治疗。更新委员会对这些文献进行了总结并提供了推荐更新。162篇文献符合标准被纳入参考。本推荐基于可改善总生存期的治疗方法。仅改善无进展生存期的治疗方法推动了对毒性及生存质量的监测。对于体力状态评分为0分或1分患者的一线治疗,可推荐以铂类为基础的细胞毒性药物的两药联用。对铂类治疗有禁忌的患者,可采用非铂类细胞毒性两药联合。对于体力状态评分为2分的患者,单一细胞毒性药物即可。对于疾病进展或经过4个周期的治疗仍对治疗无反应的患者,应停止一线细胞毒性化疗。即使在6个周期后患者对治疗仍有反应,亦应停止两药细胞毒性化疗。对于伴有明确的表皮生长因子受体(epidermal growth factor receptor,EGFR)突变的患者,可推荐一线采用吉非替尼治疗;对于EGFR突变为阴性或不明确的患者,细胞毒性化疗更佳。除具有特定临床特征的患者外,可推荐贝伐单抗与卡铂-紫杉醇联用。对于通过免疫组化证实EGFR阳性的肿瘤患者,可推荐西妥昔单抗与顺铂-长春瑞滨联用。多西紫杉醇、厄洛替尼、吉非替尼或培美曲塞被推荐作为二线治疗。对于未曾接受过厄洛替尼或吉非替尼治疗的患者,可推荐厄洛替尼作为三线治疗。现有数据不足以推荐常规三线采用细胞毒性药物。已有的证据也不足以推荐常规应用分子标记物选择化疗。 | Christopher G. AZZOLI Sherman Baker JR Sarah TEMIN William PAO Timothy ALIFF Julie BRAHMER David H. JOHNSON Janessa L. LASKIN Gregory MASTERS Daniel MILTON Luke NORDQUIST David G. PFISTER Steven PIANTADOSI Joan H. SCHILLER Reily SMITH Thomas J. SMITH John R. STRAWN David TRENT Giuseppe GIACCONE 丁燕(翻译) 南娟(翻译) 刘谦(翻译) 周清华(校对) 陈军(校对) | 2010 | 中国肺癌杂志2010，13，3： | 43 |
| 2 | A community-derived classification for extant lycophytes and ferns显示文摘发展史长通知了蕨类植物分类。当我们推断进化的树的能力改善了,针对认出生来的组的分类变得逐渐地预兆、稳定。这里,我们为 lycophytes 和蕨纲植物提供一个现代、全面分类,在下面,利用一条基于社区的途径类水平。我们 monophyly 用作主要标准让 taxa,而且目的识别保存两个广泛地被接受的存在 taxa 和界限并且与我们蕨类植物发展史的理解一致。总共,这个分类对待一在 337 个类, 51 个家庭, 14 目,和二个班估计了 11 916 种类。这个分类没在 lycophyte 和蕨纲植物上作为最后的词被打算分类,而是当前的假设的概括陈述,源于最好的可得到的数据并且在问题由熟悉植物的那些大多数塑造了。我们希望它将在蕨类植物上为最近的文学的那些想要的参考用作一个资源发展史和分类,为指导未来调查的一个框架,和推进讲话的刺激。 | Eric Schuettpelz Harald Schneider Alan R. Smith Peter Hovenkamp Jefferson Prado Germinal Rouhan Alexandre Salino Michael Sundue Thafs Elias Almeida Barbara Parris Emily B. Sessa Ashley R. Field Andre Luis de Gasper Carl J. Rothfels Michael D. Windham Marcus Lehnert Benjamin Dauphin Atsushi Ebihara Samuli Lehtonen Pedro Bond Schwartsburd Jordan Metzgar Li-Bing Zhang Li-Yaung Kuo Patrick J. Brownsey Masahiro Kato Marcelo Daniel Arana Francine C. Assis Michael S. Barker David S. Barrington Ho-Ming Chang Yi-Han Chang Yi-Shan Chao Cheng-Wei Chen De-Kui Chen Wen-Liang Chiou Vinicius Antonio de Oliveira Dittrich Yi-Fan Duan Jean-Yves Dubuisson Donald R. Farrar Susan Fawcett Jose Maria Gabriel y Galan Luiz Armando de Araujo Goes-Neto Jason R. Grant Amanda L. Grusz Christopher Haufler Warren Hauk Hai He Sabine Hennequin Regina Yoshie Hirai Layne Huiet Michael Kessler Petra Korall Paulo H. Labiak Anders Larsson Blanca Leen Chun-Xiang Li Fay-Wei Li Melanie Link-Perez Hong-Mei Liu Ngan Thi Lu Esteban I. Meza-Torres Xin-Yuan Miao Robbin Moran Claudine Massi Mynssens Nathalie Nagalingum Benjamin Ollgaard Alison M. Paul Jovani B. de S. Pereira Leon R. Perrie Monica Ponce Tom A. Ranker Christian Schulz Wataru Shinohara Alexander Shmakov Erin M. Sigel Filipe Soares de Souza Lana da Silva Sylvestre Weston Testo Luz Amparo Triana-Moreno Chie Tsutsumi Hanna Tuomisto IvAn A. Valdespino Alejandra Vasco Raquel Stauffer Viveros Alan Weakley Ran Wei Stina Weststrand Paul G. Wolf George Yatskievych Xiao-Gang Xu Yue-Hong Yan Liang Zhang Xian-Chun Zhang Xin-Mao Zhou | 2016 | Journal of Systematics and Evolution2016，54，6： | 44 |
| 3 | MicroRNAs, development of Barrett’s esophagus, and progression to esophageal adenocarcinoma显示文摘Barrett's esophagus is a premalignant condition caused by gastroesophageal reflux. Once developed, it can progress through varying grades of dysplasia to esoph-ageal adenocarcinoma. Whilst it is well accepted that Barrett's esophagus is caused by gastroesophageal reflux, the molecular mechanisms of its pathogenesis and progression to cancer remain unclear. MicroRNAs (miRNAs) are short segments of RNA that have been shown to control the expression of many human genes. They have been implicated in most cellular processes, and the role of miRNAs in disease development is be-coming increasingly evident. Understanding altered miRNA expression is likely to help unravel the molecular mechanisms that underpin the development of Barrett's esophagus and its progression to cancer. | Cameron M Smith David I Watson Michael Z Michael Damian J Hussey | 2010 | World Journal of Gastroenterology2010，16，5： | 23 |
| 4 | 选择离子流动管质谱对汽车尾气成分的分析显示文摘运用选择离子流动管质谱 (SIFT/MS)装置 ,以H3 O+ 、NO+ 、O+ 2 为初始离子对安装有催化转换装置的汽油车引擎启动 5min后的尾气进行了取样分析 ,结果表明 ,尾气中含有大量的 CH 化合物 (包括烷烃、烯烃、炔烃、二烯烃以及芳香烃 ) ,含氧有机物 (包括醛、酮、醇 )以及NH3 和NOx 等污染成分。其中 ,NO的含量最高 ,它的浓度比其它所有SIFT/MS装置所能测量到的各种物质的总和还多 ;在CH化合物中以芳香烃的含量最高 ,约占整个CH化合物含量的一半以上 ;在含氧有机物中以醛类物质的含量最高。初步讨论了这些成分的形成动力学过程 ,对引擎冷启动和热启动时的尾气成分进行了分析 ,结果表明 :冷启动尾气中CH化合物和NOx 的含量是热启动的 3~ 5倍 ,而含氧有机物的含量没有很大的变化 ,此结果也证明了尾气的催化转化装置是一种减少尾气中CH化合物和NOx 污染物的一种有效的控制方法。 | 程平 储焰南 张为俊 Patrik Spanel David Smith | 2004 | 分析化学2004，32，1： | 21 |
| 5 | Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer显示文摘AIM: To compare the efficacy of capecitabine and oxaliplatin (XELOX) with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX6) in gastric cancer patients after D2 dissection. METHODS: Between May 2004 and June 2010, patients in our gastric cancer database who underwent D2 dissection for gastric cancer at the First Affiliated Hospital of Sun Yat-Sen University were retrospectively analyzed. A total of 896 patients were enrolled into this study according to the established inclusion and exclusion criteria. Of these patients, 214 received the XELOX regimen, 48 received FOLFOX6 therapy and 634 patients underwent surgery only without chemotherapy. Overall survival was compared among the three groups using Cox regression and propensity score matchedpair analyses. RESULTS: Patients in the XELOX and FOLFOX6 groups were younger at the time of treatment (median age 55.2 years; 51.2 years vs 58.9 years), had more undifferentiated tumors (70.1%; 70.8% vs 61.4%), and more lymph node metastases (80.8%; 83.3% vs 57.7%), respectively. Overall 5-year survival was 57.3% in the XELOX group which was higher than that (47.5%) in the surgery only group (P = 0.062) and that (34.5%) in the FOLFOX6 group (P = 0.022). Multivariate analysis showed that XELOX therapy was an independent prognostic factor (hazard ratio = 0.564, P < 0.001). After propensity score adjustment, XELOX significantly increased overall 5-year survival compared to surgery only (58.2% vs 44.2%, P = 0.025) but not compared to FOLFOX6 therapy (48.5% vs 42.7%, P = 0.685). The incidence of grade 3/4 adverse reactions was similar between the XELOX and FOLFOX6 groups, and more patients suffered from hand-foot syndrome in the XELOX group (P = 0.018). CONCLUSION: Adjuvant XELOX therapy is associated with better survival in patients after D2 dissection, but does not result in a greater survival benefit compared with FOLFOX6 therapy. | Ying Wu Zhe-Wei Wei Yu-Long He Roderich E Schwarz David D Smith Guang-Kai Xia Chang-Hua Zhang | 2013 | World Journal of Gastroenterology2013，19，21： | 14 |
| 6 | miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus显示文摘AIM: To investigate miR-200 family expression in Barrett's epithelium, gastric and duodenal epithelia, and esophageal adenocarcinoma. METHODS: Real-time reverse transcriptase-polymerase chain reaction was used to measure miR-200, ZEB1 and ZEB2 expression. Ingenuity Pathway Analysis of miR-200 targets was used to predict biological outcomes. RESULTS: Barrett's epithelium expressed lower levels of miR-141 and miR-200c than did gastric and duodenal epithelia (P < 0.001). In silico analysis indicated roles for the miR-200 family in molecular pathways that distinguish Barrett's epithelium from gastric and duodenalepithelia, and which control apoptosis and proliferation. All miR-200 members were downregulated in adenocarcinoma (P < 0.02), and miR-200c expression was also downregulated in non-invasive epithelium adjacent to adenocarcinoma (P < 0.02). The expression of all miR-200 members was lower in Barrett's epithelium derived high-grade dysplastic cell lines than in a cell line derived from benign Barrett's epithelium. We observed signif icant inverse correlations between miR-200 family expression and ZEB1 and ZEB2 expression in Barrett's epithelium and esophageal adenocarcinoma (P < 0.05). CONCLUSION: miR-200 expression might contribute to the anti-apoptotic and proliferative phenotype of Barrett's epithelium and regulate key neoplastic processes in this epithelium. | Cameron M Smith David I Watson Mary P Leong George C Mayne Michael Z Michael Bas PL Wijnhoven Damian J Hussey | 2011 | World Journal of Gastroenterology2011，17，8： | 13 |
| 7 | 将卒中纳入心血管风险预测工具美国心脏协会/美国卒中协会对医疗卫生专业人员的声明显示文摘背景和目的目前美国针对心血管事件风险预测以及一级和二级预防的指南声明均使用绝对风险估计值来识别血管事件高危患者以及可从特定干预措施中获益的患者。然而,这些指南并未明确地包括卒中患者。本指南对现有证据和争论进行概述以支持:(1)将卒中(尤其是动脉粥样硬化性卒中)患者纳入心血管病绝对风险增高的患者群体;(2)将卒中纳入血管性疾病风险预测工具的转归预测因素。方法和结果写作组成员由委员会联合主席基于先前在相关领域的研究成果来提名,并得到美国心脏协会(American Heart Association,AHA)卒中委员会科学声明监督委员会以及文稿监督委员会的批准。作者采用系统文献回顾(覆盖1980年1月至2010年3月期间的文献)并参考以往公布的指南、个人资料以及专家观点,以归纳现有证据,提出当前知识的不足,并根据AHA标准对适当的问题制定推荐意见。所有写作组成员均有机会对推荐意见进行评论并批准了最终版本。经广泛的AHA内部同行评议以及卒中委员会领导阶层和科学声明监督委员会的审阅后,最终获得AHA科学咨询和协调委员会的批准。将卒中患者(尤其是动脉粥样硬化性卒中患者)纳入冠状动脉和心血管病绝对高危人群的原因如下。首先,有证据显示,缺血性卒中患者发生致死性和非致死性心肌梗死或猝死的绝对风险增高,10年绝对风险≥20%,这一风险阈值已被一些指南用于定义冠状动脉疾病风险等危症。其次,纳入动脉粥样硬化性卒中的原因与纳入糖尿病、周围血管病、慢性肾脏病以及其他动脉粥样硬化性疾病的原因相同,尽管尚缺乏在所有人群或患者中风险增高的统一证据。再次,缺血性卒中的大动脉粥样硬化性卒中亚型与其他这些疾病的病理生理学机制相同。将卒中纳入高危因素将导致高危人群的数量扩大约10%。然而,由于卒中的异质性,尚不确定其他卒中亚型,包括出血性卒中以及非动脉粥样硬化性卒中亚型,是否应被视为具有相同水平的风险,因此有待进一步研究。鉴于卒中对残疾和死亡的影响、卒中与其他血管性疾病预防措施的相似性以及卒中在某些人群中较冠状动脉疾病更高的重要性,将卒中、心肌梗死和猝死纳入心血管事件风险预测工具的转归预测因素是合适的。美国以外的指南常常将卒中患者纳入心血管高危人群,并将卒中作为心脏终点的一个相关转归事件。结论动脉粥样硬化性卒中患者应被纳入会进一步发生冠状动脉粥样硬化事件的高危患者(10年≥20%)。是否应纳入非动脉粥样硬化卒中亚型尚不确定。对于一级预防,缺血性卒中应被纳入绝对风险评估方案的心血管疾病转归事件。将动脉粥样硬化性卒中作为一个高危因素或者更宽泛地将缺血性卒中视作一种转归事件纳入,可能对心血管病的预防具有重要意义,因为被评定为高危风险的患者数量将大幅增加。 | Daniel T. Lackland Mitchell S.V. Elkind Ralph D'Agostino Sr Mandip S. Dhamoon David C. Goff Jr Randall T. Higashida Leslie A. McClure Pamela H. Mitchell Ralph L. Sacco Cathy A. Sila Sidney C. Smith Jr David Tanne David L. Tirschwell Emmanuel Touze Lawrence R. Wechsler 4:~ 尤寿江(译) 于海龙(译) 刘慧慧(译) 张霞(译) 刘春风(译) | 2012 | 国际脑血管病杂志2012，20，11： | 13 |
| 8 | 用选择离子流动管质谱测定汽油和柴油蒸汽成分显示文摘采用选择离子流动管质谱(SIFT/MS)装置,以H3O+、NO+为初始离子对汽油和柴油蒸汽进行了研究,质谱分析表明,汽油和柴油主要由C-H化合物组成.包括烷烃、环烷烃、烯烃、炔烃、二烯烃以及芳香烃。在这几种成分中,烷烃都占有最大的比例;汽油蒸汽和柴油蒸汽最大的区别是柴油蒸汽中长链大分子的挥发性C-H化合物所占的比例远远高于汽油蒸汽。文中还给出了以H3O+、NO+为初始离子所得到的汽油蒸汽的质谱图,以及汽油、柴油蒸汽中各种成分的定量分析结果。 | 程平 张为俊 储焰南 Patrik Spanel David Smith | 2003 | 分析化学2003，31，5： | 13 |
| 9 | 伴有脑肿胀的大脑和小脑梗死的管理推荐意见美国心脏协会/美国卒中协会对医疗专业人员的声明显示文摘背景和目的关于缺血性卒中后脑肿胀患者的最佳管理方案,仍有许多尚未确定的问题。需要制定相关指南来指导如何处理这种严重并发症,如何提供最佳的综合性神经科和内科治疗,以及在患者病情恶化时如何与面临外科干预复杂决策的家属进行良好的沟通。本科学声明为大脑或小脑半球缺血性卒中伴脑肿胀的患者提供了早期的管理方案。方法写作组利用系统文献综述,参考公开发表的临床和流行病学研究、发病率和死亡率报告、临床与公共卫生指南、权威声明、个人文件以及专家意见,对现有证据进行总结并指出与当前知识水平的差距。写作组通过对MEDLINE、EMBASE和Web of Science数据库进行医学文献计算机检索(最后检索时间为2013年3月,研究对象为成年人)回顾最相关的文献。在美国心脏协会(American Heart Association,ARIA)框架背景下对证据进行组织,根据AHA/美国心脏病学学会基金会以及AHA卒中委员会的证据强度分级方案进行分类。这份声明经过AHA内部的广泛同行评议。结果已有适用于由缺血性梗死引起的半球(累及整个大脑中动脉供血区或更大范围)和小脑(累及小脑后下动脉或小脑上动脉供血区)肿胀的临床标准。幕上半球缺血性卒中伴脑肿胀发生恶化的临床表现包括新发意识障碍或意识障碍加重、脑性上睑下垂以及瞳孔大小变化。在小脑梗死伴肿胀患者中,意识水平下降是脑干受压的结果,因此可能出现早期角膜反射丧失和瞳孔缩小。应制定标准化定义以促进多中心和基于人群的发病率、患病率、危险因素和转归研究。脑肿胀高危患者的识别应包括临床和神经影像学资料。如果大面积卒中患者有必要进入全面复苏状态,则需要收入具备神经监护功能的病房。这些患者最好被收入由技术熟练和经验丰富的医生(如神经重症监护医生或神经血管科医生)负责的重症监护室或卒中单元。综合性医疗管理包括气道管理和机械通气、血压控制、液体管理以及血糖和体温控制。在幕上半球缺血性卒中伴肿胀患者中,不需行常规颅内压监测或脑脊液引流,但神经功能继续恶化的患者应考虑行去骨瓣减压和硬脑膜切开术。去骨瓣减压术在≥60岁的患者中的疗效尚不确定。在神经功能恶化的小脑卒中伴肿胀患者中,应行枕骨下颅骨切除和硬脑膜切开术。当应用脑室造瘘术缓解小脑梗死后梗阻性脑积水时,应同时行枕骨下颅骨切除术以防小脑向上移位导致的病情恶化。幕上半球梗死伴肿胀患者可获得令人满意的转归,但即使行去骨瓣减压术,仍有1/3的患者会遗留严重残疾和完全生活依赖。多数小脑梗死患者在术后能获得可接受的功能转归。结论大脑和小脑梗死伴肿胀是需要立即给予专业神经重症监护、并常需要进行神经外科干预的危重情况。去骨瓣减压术是很多患者的必然治疗选择,经过选择的患者能从中受益匪浅,尽管他们可能会遗留残疾,但仍可生活自理。 | Eelco F. M. Wijdicks Kevin N. Sheth Bob S. Carter David M. Greer Scott E. Kasner W. Taylor Kimberly Stefan Schwab Eric E. Smith Rafael J. Tamargo Max Wintermark 王玉琴 牛牧 柯开富 | 2014 | 国际脑血管病杂志2014，22，4： | 11 |
| 10 | Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial显示文摘 | Tom Waddell Ian Chau David Cunningham David Gonzalez Alicia Frances Clare Okines Andrew Wotherspoon Claire Saffery Gary Middleton Jonathan Wadsley David Ferry Wasat Mansoor Tom Crosby Fareeda Coxon David Smith Justin Waters Timothy Iveson Stephen Falk Sar | 2013 | Lancet Oncology2013，，6： | 10 |
| 11 | Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline From the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology显示文摘 | Bernard Levin David A. Lieberman Beth McFarland Kimberly S. Andrews Durado Brooks John Bond Chiranjeev Dash Francis M. Giardiello Seth Glick David Johnson C. Daniel Johnson Theodore R. Levin Perry J. Pickhardt Douglas K. Rex Robert A. Smith Alan Thorson S | 2008 | Gastroenterology2008，，5： | 8 |
| 12 | Neuronal failure in Alzheimer's disease: a view through the oxidative stress looking-glass显示文摘Considerable debate and controversy surround the cause(s) of Alzheimer's disease(AD). To date, several theories have gained notoriety, however none is universally accepted. In this review, we provide evidence for the oxidative stress-induced AD cascade that posits aged mitochondria as the critical origin of neurodegeneration in AD. | David J. Bonda Xinglong Wang Hyoung-Gon Lee Mark A. Smith George Perry Xiongwei Zhu | 2014 | Neuroscience Bulletin2014，30，2： | 7 |
| 13 | Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement显示文摘 | Scott M. Grundy James I. Cleeman Stephen R. Daniels Karen A. Donato Robert H. Eckel Barry A. Franklin David J. Gordon Ronald M. Krauss Peter J. Savage Sidney C. Smith John A. Spertus Fernando Costa | 2005 | Circulation2005，，17： | 7 |
| 14 | Determinants of the impact of blood pressure variability on neurological outcome after acute ischaemic stroke显示文摘Introduction: Increased blood pressure variability (BPV) is detrimental after acute ischaemic stroke, but the interaction between BPV and neuroimaging factors that directly influence stroke outcome has not been explored. Methods: We retrospectively reviewed inpatients from 2007 to 2014 with acute anterior circulation ischaemic stroke, CT perfusion and angiography at hospital admission, and a modified Rankin Scale (MRS) 30- 365 days after stroke onset. BPV indices included SD, coefficient of variation and successive variation of the systolic blood pressure between 0 and 120 hours after admission. Ordinal logistic regression models were fitted to MRS with predictor variables of BPV indices. Models were further stratified by CT perfusion volumetric measurements, proximal vessel occlusion and collateral score. Results: 110 patients met the inclusion criteria. The likelihood of a 1-point rise in the MRS increased with every 10 mm Hg increase in BPV (OR for the 3 BPV indices ranged from 2.27 to 5.54), which was more pronounced in patients with larger ischaemic core volumes (OR 8.37 to 18.0) and larger hypoperfused volumes (OR 6.02 to 15.4). This association also held true for patients with larger mismatch volume, proximal vessel occlusion and good collateral vessels. Conclusions: These results indicate that increased BPV is associated with worse neurological outcome after stroke, particularly in patients with a large lesion core volume, concurrent viable ischaemic penumbra, proximal vessel occlusion and good collaterals. This subset of patients, who are often not candidates for or fail acute stroke therapies such as intravenous tissue plasminogen activator or endovascular thrombectomy, may benefit from interventions aimed at reducing BPV. | Adam de Havenon Alicia Bennett Gregory J Stoddard Gordon Smith Lee Chung Steve O’Donnell J Scott McNally David Tirschwell Jennifer J Majersik | 2017 | Stroke & Vascular Neurology2017，2，1： | 6 |
| 15 | Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial显示文摘 | Pierre J Guillou Philip Quirke Helen Thorpe Joanne Walker David G Jayne Adrian MH Smith Richard M Heath Julia M Brown | 2005 | The Lancet . 2005 (9472)2005，，9472： | 6 |
| 16 | 代谢综合征的诊断和治疗——美国心脏协会/国立心肺血液研究所指南概要显示文摘 | Scott M. Grundy James I. Cleeman Stephen R. Daniels Karen A. Donato Robert H. Eckel Barry A.Franklin David J. Gordon Ronald M. Krauss Peter J. Savage Sidney C. Smith John A. Spertus Fernando Costa | 2006 | 世界核心医学期刊文摘(心脏病学分册)2006，2，4： | 5 |
| 17 | 潮湿空气微波放电离子形成动力学显示文摘利用微波放电电离质谱装置,通过水蒸气与空气混合气体(潮湿空气)的微波放电,同时获得了化学电离质谱探测技术中常用的三种重要母体离子H3O+、NO+和O2+.结合潮湿空气中主要成分N2、O2以及水蒸气各自微波放电后的质谱探测结果,对潮湿空气微波放电后上述三种离子产生的动力学过程进行了分析,并给出了各种离子的形成机制.这些离子-分子反应过程在计算机模拟中得到了进一步的证实. | 程平 王鸿梅 李建权 张为俊 纪玉峰 王振亚 盛六四 Patrik Spanel David Smith 曹德兆 储焰南 | 2002 | 物理化学学报2002，18，3： | 5 |
| 18 | Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial显示文摘 | Pierre J Guillou Philip Quirke Helen Thorpe Joanne Walker David G Jayne Adrian MH Smith Richard M Heath Julia M Brown | 2005 | The Lancet2005，，9472： | 4 |
| 19 | Particulate Matter Air Pollution and Cardiovascular Disease: An Update to the Scientific Statement From the American Heart Association显示文摘 | Robert D. Brook Sanjay Rajagopalan C. Arden Pope Jeffrey R. Brook Aruni Bhatnagar Ana V. Diez-Roux Fernando Holguin Yuling Hong Russell V. Luepker Murray A. Mittleman Annette Peters David Siscovick Sidney C. Smith Laurie Whitsel Joel D. Kaufman | 2010 | Circulation2010，，21： | 4 |
| 20 | 甲醛固定石蜡包埋组织中DNA的降解情况显示文摘 | 田子强 刘俊峰 王贵英 Eric Smith Paul Drew David Watson Glyn G Jamieson | 2004 | 中华病理学杂志2004，33，3： | 4 |
您所在的机构暂未开通此部分的功能，请联系管理员